August 13, 2015 | Teva Pharmaceutical Industry’s new drug application for Huntington’s Disease medication was approved by the US Food & Drug Administration. The drug, SD-809, was approved for the treatment of chorea, a neurological disorder associated with Huntington’s Disease. The trial drug SD-809 was added to Teva’s portfolio after the pharmaceutical company acquired Auspex for $3.2 billion in May 2015. Teva was founded in 1901 and is headed by CEO Erez Vigodman.
Subscribe to NoCamels weekly newsletter and get our top stories
Related posts

Israeli AI Safety Tool Among TIME’S Best Inventions For 2024
October 31, 2024

TAU Team Discovers Mechanism To Eliminate Cancerous Tumors
October 30, 2024

Ashdod Port Investing In Startups As Part Of Innovation Strategy
October 29, 2024

BGU Develops Fast Fact Checking Via News Sources Not People
October 28, 2024
Facebook comments